Abstract

This is another report from the discontinued, estrogen-progestin arm of the WHI's hormone therapy trial (Journal Watch Women's Health Aug 7 2002). In this arm of the trial, 16,608 women were randomly assigned to receive either placebo or conjugated estrogens (0.625 mg/day) plus medroxyprogesterone acetate (2.5 mg/day). When this arm was stopped, HT recipients showed a significantly lower risk for colorectal cancer compared with placebo recipients. Now, WHI investigators have evaluated the features of …

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call